Anti-Kinase (Targeted Drug)
Overview Cancer (medical term: malignant neoplasm) is a class of diseases in which a group of cells display the traits of uncontrolled growth (growth and division beyond the normal limits), invasion (intrusion on and destruction of adjacent tissues), and sometimes metastasis (spread to other locations in the body via lymph or blood). These three malignant properties of cancers differentiate them from benign tumors, which are self-limited, do not invade or metastasize.
Protein tyrosine kinases are enzymes that provide a central switch mechanism in cellular signal transduction pathways. As such they are involved in many cellular processes such as cell proliferation, metabolism, survival and apoptosis. Several protein tyrosine kinases are known to be activated in cancer cells and to drive tumour growth and progression.
Blocking tyrosine kinase activity therefore represents a rational approach to cancer therapy. Therapeutic strategies include blocking kinase-substrate interaction, inhibiting the enzyme's adenosine triphosphate (ATP) binding site and blocking extracellular tyrosine kinase receptors on tumour cells. Already several tyrosine kinase inhibitors have been approved as anti-cancer agents, including Iressa (AstraZenecz), Tarceva (Roche), and Nexavar (Bayer&Onyx).
In vitro test report—Suppression of liver cancer cell growth rate
Screening method: Sulforhodamine B. SRB
Cell line: BEL-7402 Human liver cancer cell
Experience duration: 72 hours
Result: No activity: 10-5mol/L<85%
Mild activity: 10-5mol/L＞85% or 10-6mol/L＞50%
Significant activity: 10-6mol/L＞85% or 10-7mol/L＞50%
Summary
Major finding in Lee’s pathological diagnosis on April 27th, 2007 is the favored multi-nodular HCCs at both lobes, and the largest one is about 3.1 cm. At first the patient was treated by Iressa anti-cancer drug, but it caused the severe allergy drug reaction. Moreover, in the beginning of the October, 2007, Lee was diagnosed that there is a sizeable tumor on eyes, which was originally planed to remove it in the middle of November. The size of the lung tumor was 5 cm. Instead, without other treatments, Lee changed to use the anti-cancer peptide drug in our company. On October 31st, Lee’s AFP was tested 172.1 ng/ml, and the following month, on November 14th, the number lowered to 106.9. Besides that, the tumor on eyes totally disappeared. On November 15th, the test result of GPT and GOT were 78 U/L and 70 U/L. However, according to the latest result, which was tested on February 26th, 2008, the multi-tumor has disappeared, and the biggest size of liver tumor is shrunk from 3.1 cm to 3x2.5 cm; furthermore, GPT and GOT are lower to 57 U/L and 67 U/L. Also, the test result of AFP is even lower to 31.3 ng/ml. Moreover, the original lung tumor size was 5 cm was shrunk to 3.6 cm in March 2008. According to the daughter, the patient was asked to check back once a month, and then after using our drug, the patient was asked to check back once in 2 months. Finally, recently the doctor asks the patient to check back once in 3 months. The patient even can take HSR for traveling. It all demonstrates how affective this Anti-cancer peptide drug is.
Overview Cancer (medical term: malignant neoplasm) is a class of diseases in which a group of cells display the traits of uncontrolled growth (growth and division beyond the normal limits), invasion (intrusion on and destruction of adjacent tissues), and sometimes metastasis (spread to other locations in the body via lymph or blood). These three malignant properties of cancers differentiate them from benign tumors, which are self-limited, do not invade or metastasize.
Protein tyrosine kinases are enzymes that provide a central switch mechanism in cellular signal transduction pathways. As such they are involved in many cellular processes such as cell proliferation, metabolism, survival and apoptosis. Several protein tyrosine kinases are known to be activated in cancer cells and to drive tumour growth and progression.
Blocking tyrosine kinase activity therefore represents a rational approach to cancer therapy. Therapeutic strategies include blocking kinase-substrate interaction, inhibiting the enzyme's adenosine triphosphate (ATP) binding site and blocking extracellular tyrosine kinase receptors on tumour cells. Already several tyrosine kinase inhibitors have been approved as anti-cancer agents, including Iressa (AstraZenecz), Tarceva (Roche), and Nexavar (Bayer&Onyx).
In vitro test report—Suppression of liver cancer cell growth rate
Screening method: Sulforhodamine B. SRB
Cell line: BEL-7402 Human liver cancer cell
Experience duration: 72 hours
Result: No activity: 10-5mol/L<85%
Mild activity: 10-5mol/L＞85% or 10-6mol/L＞50%
Significant activity: 10-6mol/L＞85% or 10-7mol/L＞50%
Summary
Major finding in Lee’s pathological diagnosis on April 27th, 2007 is the favored multi-nodular HCCs at both lobes, and the largest one is about 3.1 cm. At first the patient was treated by Iressa anti-cancer drug, but it caused the severe allergy drug reaction. Moreover, in the beginning of the October, 2007, Lee was diagnosed that there is a sizeable tumor on eyes, which was originally planed to remove it in the middle of November. The size of the lung tumor was 5 cm. Instead, without other treatments, Lee changed to use the anti-cancer peptide drug in our company. On October 31st, Lee’s AFP was tested 172.1 ng/ml, and the following month, on November 14th, the number lowered to 106.9. Besides that, the tumor on eyes totally disappeared. On November 15th, the test result of GPT and GOT were 78 U/L and 70 U/L. However, according to the latest result, which was tested on February 26th, 2008, the multi-tumor has disappeared, and the biggest size of liver tumor is shrunk from 3.1 cm to 3x2.5 cm; furthermore, GPT and GOT are lower to 57 U/L and 67 U/L. Also, the test result of AFP is even lower to 31.3 ng/ml. Moreover, the original lung tumor size was 5 cm was shrunk to 3.6 cm in March 2008. According to the daughter, the patient was asked to check back once a month, and then after using our drug, the patient was asked to check back once in 2 months. Finally, recently the doctor asks the patient to check back once in 3 months. The patient even can take HSR for traveling. It all demonstrates how affective this Anti-cancer peptide drug is.